A detailed history of Rhumbline Advisers transactions in Annexon, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 126,659 shares of ANNX stock, worth $890,412. This represents 0.0% of its overall portfolio holdings.

Number of Shares
126,659
Previous 81,978 54.5%
Holding current value
$890,412
Previous $587,000 5.62%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 01, 2024

BUY
$4.33 - $6.79 $193,468 - $303,383
44,681 Added 54.5%
126,659 $620,000
Q1 2024

May 09, 2024

BUY
$4.03 - $7.81 $91,311 - $176,958
22,658 Added 38.2%
81,978 $587,000
Q4 2023

Feb 08, 2024

SELL
$1.63 - $4.63 $635 - $1,805
-390 Reduced 0.65%
59,320 $269,000
Q3 2023

Nov 09, 2023

BUY
$2.13 - $3.84 $9,968 - $17,971
4,680 Added 8.5%
59,710 $140,000
Q2 2023

Aug 08, 2023

BUY
$2.1 - $6.37 $115,563 - $350,541
55,030 New
55,030 $193,000
Q2 2022

Aug 11, 2022

SELL
$2.11 - $4.06 $82,114 - $158,003
-38,917 Closed
0 $0
Q1 2022

May 12, 2022

BUY
$2.73 - $11.94 $3,117 - $13,635
1,142 Added 3.02%
38,917 $106,000
Q4 2021

Feb 10, 2022

SELL
$11.49 - $22.0 $5,813 - $11,132
-506 Reduced 1.32%
37,775 $434,000
Q3 2021

Nov 12, 2021

BUY
$16.35 - $23.4 $24,116 - $34,515
1,475 Added 4.01%
38,281 $712,000
Q2 2021

Aug 05, 2021

BUY
$17.81 - $27.48 $203,212 - $313,546
11,410 Added 44.93%
36,806 $829,000
Q1 2021

May 06, 2021

BUY
$22.0 - $35.01 $211,706 - $336,901
9,623 Added 61.01%
25,396 $707,000
Q4 2020

Feb 10, 2021

BUY
$20.81 - $30.55 $55,292 - $81,171
2,657 Added 20.26%
15,773 $395,000
Q3 2020

Nov 12, 2020

BUY
$17.5 - $30.23 $229,530 - $396,496
13,116 New
13,116 $396,000

Others Institutions Holding ANNX

About Annexon, Inc.


  • Ticker ANNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 47,617,700
  • Market Cap $335M
  • Description
  • Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated n...
More about ANNX
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.